Mirabegron & Solifenacin Tablets ER 50/5 Mg

What Is Mirabegron & Solifenacin Tablets ER 50/5 Mg?

Mirabegron & Solifenacin Tablets ER 50/5 Mg is an extended-release oral combination tablet intended for adult patients with overactive bladder symptoms. The fixed-dose combination allows consistent therapeutic coverage throughout the day and improves treatment adherence through once-daily dosing.

How Mirabegron & Solifenacin Tablets ER 50/5 Mg Work

Mirabegron & Solifenacin Tablets ER 50/5 Mg work by relaxing the bladder muscles and reducing involuntary bladder contractions, helping improve bladder control in patients with overactive bladder.
Clinical studies support the effectiveness of Mirabegron and Solifenacin combination therapy for overactive bladder in patients who do not achieve adequate symptom relief with single-agent treatment.

Mechanism of Action

• Mirabegron activates beta-3 adrenergic receptors to relax detrusor smooth muscle

• Solifenacin blocks muscarinic receptors to reduce involuntary bladder contractions

• Increases bladder storage capacity

• Reduces urinary urgency, frequency, and urge incontinence episodes

This dual approach helps improve quality of life in patients with persistent overactive bladder symptoms.

Uses of Mirabegron & Solifenacin Tablets ER 50/5 Mg

Mirabegron & Solifenacin Tablets ER 50/5 Mg are prescribed for the management of overactive bladder symptoms.
Patients and healthcare providers can explore related urology medicines for overactive bladder for additional therapeutic options and treatment combinations.

Therapeutic Indications

• Treatment of overactive bladder (OAB)

• Reduction of urinary urgency

• Decrease in frequency of urination

• Management of urge urinary incontinence

• Patients requiring combination therapy for improved symptom control

Dosage and Administration

The dosage of Mirabegron & Solifenacin Tablets ER 50/5 Mg should be prescribed by a qualified healthcare professional.

Administration Guidelines

• Taken once daily by mouth

• Swallow the tablet whole with water

• Can be taken with or without food

• Do not crush, chew, or split the tablet

• Do not stop treatment without medical advice

Dose adjustments may be required based on patient response and tolerability.

Side Effects of Mirabegron & Solifenacin Tablets ER 50/5 Mg

Some patients may experience side effects during treatment.

Common Side Effects

• Dry mouth

• Constipation

• Headache

• Increased blood pressure

• Urinary tract infection

Less Common Side Effects

• Dizziness

• Blurred vision

• Palpitations

• Abdominal discomfort

• Allergic skin reactions

Patients should seek medical attention if severe or persistent side effects occur.

Warnings and Precautions

Patients should follow professional medical advice and review Mirabegron extended-release tablets medical information for complete safety, dosage, and contraindication details.

Important Safety Information

• Not recommended for patients with severe uncontrolled hypertension

• Use with caution in patients with urinary retention or gastric retention

• Blood pressure monitoring may be advised

• Use during pregnancy or breastfeeding only if prescribed

• Avoid abrupt discontinuation without medical advice

Solifenacin FDA Prescribing Information (DailyMed) – Official FDA-approved prescribing, dosage, contraindications, and safety information for solifenacin is available through the DailyMed database.

Storage Instructions

• Store below 25 °C

• Protect from moisture and direct sunlight

• Keep out of reach of children

  FAQ’s